311 related articles for article (PubMed ID: 24901360)
1. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma.
OʼReilly EM; Perelshteyn A; Jarnagin WR; Schattner M; Gerdes H; Capanu M; Tang LH; LaValle J; Winston C; DeMatteo RP; DʼAngelica M; Kurtz RC; Abou-Alfa GK; Klimstra DS; Lowery MA; Brennan MF; Coit DG; Reidy DL; Kingham TP; Allen PJ
Ann Surg; 2014 Jul; 260(1):142-8. PubMed ID: 24901360
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
[TBL] [Abstract][Full Text] [Related]
3. NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer.
Sahora K; Kuehrer I; Eisenhut A; Akan B; Koellblinger C; Goetzinger P; Teleky B; Jakesz R; Peck-Radosavljevic M; Ba'ssalamah A; Zielinski C; Gnant M
Surgery; 2011 Mar; 149(3):311-20. PubMed ID: 20817204
[TBL] [Abstract][Full Text] [Related]
4. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.
Kim EJ; Ben-Josef E; Herman JM; Bekaii-Saab T; Dawson LA; Griffith KA; Francis IR; Greenson JK; Simeone DM; Lawrence TS; Laheru D; Wolfgang CL; Williams T; Bloomston M; Moore MJ; Wei A; Zalupski MM
Cancer; 2013 Aug; 119(15):2692-700. PubMed ID: 23720019
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma.
Serrano PE; Herman JM; Griffith KA; Zalupski MM; Kim EJ; Bekaii-Saab TS; Ben-Josef E; Dawson LA; Ringash J; Wei AC
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):270-7. PubMed ID: 25104069
[TBL] [Abstract][Full Text] [Related]
6. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience.
Leone F; Gatti M; Massucco P; Colombi F; Sperti E; Campanella D; Regge D; Gabriele P; Capussotti L; Aglietta M
Cancer; 2013 Jan; 119(2):277-84. PubMed ID: 22778019
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
Christians KK; Tsai S; Mahmoud A; Ritch P; Thomas JP; Wiebe L; Kelly T; Erickson B; Wang H; Evans DB; George B
Oncologist; 2014 Mar; 19(3):266-74. PubMed ID: 24569947
[TBL] [Abstract][Full Text] [Related]
8. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
10. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01).
Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S;
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin.
Palmer DH; Stocken DD; Hewitt H; Markham CE; Hassan AB; Johnson PJ; Buckels JA; Bramhall SR
Ann Surg Oncol; 2007 Jul; 14(7):2088-96. PubMed ID: 17453298
[TBL] [Abstract][Full Text] [Related]
13. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.
Katz MHG; Ou FS; Herman JM; Ahmad SA; Wolpin B; Marsh R; Behr S; Shi Q; Chuong M; Schwartz LH; Frankel W; Collisson E; Koay EJ; Hubbard JM; Leenstra JL; Meyerhardt J; O'Reilly E;
BMC Cancer; 2017 Jul; 17(1):505. PubMed ID: 28750659
[TBL] [Abstract][Full Text] [Related]
14. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
Motoi F; Satoi S; Honda G; Wada K; Shinchi H; Matsumoto I; Sho M; Tsuchida A; Unno M;
J Gastroenterol; 2019 Feb; 54(2):194-203. PubMed ID: 30182219
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
Berriochoa CA; Abdel-Wahab M; Leyrer CM; Khorana A; Matthew Walsh R; Kumar AMS
J Dig Dis; 2017 Nov; 18(11):642-649. PubMed ID: 29055078
[TBL] [Abstract][Full Text] [Related]
16. Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy.
Chao YJ; Sy ED; Hsu HP; Shan YS
BMC Surg; 2014 Sep; 14():72. PubMed ID: 25258022
[TBL] [Abstract][Full Text] [Related]
17. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer.
Sho M; Akahori T; Tanaka T; Kinoshita S; Tamamoto T; Nomi T; Yamato I; Hokuto D; Yasuda S; Kawaguchi C; Nishiofuku H; Marugami N; Enomonoto Y; Kasai T; Hasegawa M; Kichikawa K; Nakajima Y
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):197-205. PubMed ID: 22766692
[TBL] [Abstract][Full Text] [Related]
18. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience.
Gusani NJ; Balaa FK; Steel JL; Geller DA; Marsh JW; Zajko AB; Carr BI; Gamblin TC
J Gastrointest Surg; 2008 Jan; 12(1):129-37. PubMed ID: 17851723
[TBL] [Abstract][Full Text] [Related]
19. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial.
Versteijne E; van Eijck CH; Punt CJ; Suker M; Zwinderman AH; Dohmen MA; Groothuis KB; Busch OR; Besselink MG; de Hingh IH; Ten Tije AJ; Patijn GA; Bonsing BA; de Vos-Geelen J; Klaase JM; Festen S; Boerma D; Erdmann JI; Molenaar IQ; van der Harst E; van der Kolk MB; Rasch CR; van Tienhoven G;
Trials; 2016 Mar; 17(1):127. PubMed ID: 26955809
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.
Golcher H; Brunner TB; Witzigmann H; Marti L; Bechstein WO; Bruns C; Jungnickel H; Schreiber S; Grabenbauer GG; Meyer T; Merkel S; Fietkau R; Hohenberger W
Strahlenther Onkol; 2015 Jan; 191(1):7-16. PubMed ID: 25252602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
